“I want to tell you about a new cancer fighting biotech name that’s probably not on your radar screen,” said Cramer.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
In two big M&A deals, Valeant Pharmaceuticals agreed to buy Bausch & Lomb for $8.7 billion, and AstraZeneca agreed to acquire Omthera Pharmaceuticals for as much as $443 million.
Merck inked a $5 billion share repurchase agreement with Goldman Sachs, as the drug giant looks to prop up shareholder value in face of competition from generics makers.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
A 65-year-old couple retiring this year would need $220,000 on average to cover medical expenses, an 8 percent decrease from last year's estimate. But most people estimate just a fraction of that.
Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.
The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.
Shares of genetic test maker rose 4 percent, after actress Anjolina Jolie said to undergo double-mastectomy, following testing which showed she carried a gene for breast cancer.
CFO Simon Dingemans says GlaxoSmithKline's re-engineered approach to R&D is bearing fruit.
Cramer doesn’t ordinarily recommend fresh IPOs immediately in the aftermarket. This one, however, is an exception.
Under President Barack Obama's health care law, where you live could make a huge difference in what you'll pay for medications.
Massachusetts has had Romneycare since 2006. And, while it's different in some ways from Obamacare, it offers insight into what's ahead for US health care.
Saurabh Mukherjea, Head of Equities at Ambit Capital talks to Cash Flow about where to invest in India's pharmaceutical market.
An antibiotic-resistant strain of gonorrhea has some saying that its effects could match those of AIDS.
Rolf-Dieter Schwalb, CFO of DSM, tells CNBC that whilst the nutrition business is doing well, pharma needs improvement.
If you’re selling drug stocks for this reason, Cramer thinks you don’t get the pharma business.
The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.